Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.  Laurence Belkoff, DO, FACOS, Chairman of the Department of Specialty Surgeries and the Division of Urology at the Philadelphia College of Osteopathic Medicine presented the results during the late-breaking science forum. The top-line results had been previously reported; however, the presentation by Dr. Belkoff marks the first time these results have been presented at a major medical meeting.

The study met all primary endpoints by demonstrating sustained improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP 2 and SEP 3) and improvements in the International Index of Erectile Function (IIEF).  The study also indicated that successful intercourse (as measured by SEP 3) was achieved as early as 15 minutes, consistent with results from previously reported phase 3 double-blind, placebo-controlled studies.

"The avanafil data from the open label, long-term safety study confirm the safety and efficacy results previously observed in the two placebo-controlled trials," commented Dr. Belkoff.  "The safety profile demonstrated during the year-long study and successful intercourse attempts within 15 minutes of dosing suggest avanafil, if approved, may be an attractive treatment option for men with ED."

Highlights of the TA-314 study include:

  • Eighty percent (80%) of sexual attempts among patients on avanafil resulted in erections sufficient for intercourse (SEP 2)
  • Erectil
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... Akcea Therapeutics, a wholly-owned subsidiary of ... today that the U.S. Food and Drug Administration ... Rx ) for the treatment of patients with ... genetic disease characterized by extremely high triglyceride levels ... study published in the NEJM in December 2014, ...
    (Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
    (Date:7/5/2015)... -- Nihon University is pleased to announce that ... "Medicine Definitely Jumps Up with 8K" will be ... Tokyo, Japan . Many experts on imaging ... their achievements and future prospects on progress of ... 8K technology. (Documentation: http://prw.kyodonews.jp/prwfile/release/M000079/201507031722/_prw_OA1fl_Xy4Q5W4x.pdf ) ...
    Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3
    ... Nov. 3 Sirion Therapeutics, Inc., a,privately ... of two investigational drugs in development for,treatment ... presented at,upcoming ophthalmology meetings: At the American ... Marriott Marquis, Atlanta),preliminary results will be presented ...
    ... in this Under-Studied Condition, SAN DIEGO, Nov. ... release tablets (paliperidone ER),for six weeks showed a ... study presented today at the U.S. Psychiatric & ... safety findings were similar,to published studies of paliperidone ...
    Cached Medicine Technology:Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 2Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 3Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 4Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6
    (Date:7/6/2015)... ... 2015 , ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella ... a non-surgical method to dissolve fat cells and is the first of its kind ... the chin, commonly known as a double chin. Dr. Green participated in clinical trials ...
    (Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Diabetes affects ... help. More than 29 million Americans have diabetes, the majority of which are Type ... U.S. adults or more than one in three, have prediabetes (abnormally high blood sugar ...
    (Date:7/5/2015)... ... July 06, 2015 , ... Security ... excited to announce the next generation of PrimeStar Individual Dental Insurance. Beginning now, ... include two network options—Maximum Allowable Charge (MAC) and usual, customary and reasonable (UCR). ...
    (Date:7/5/2015)... ... July 05, 2015 , ... World Patent Marketing, ... a landscaping invention that effectively removes weeds without harming man and nature. ... Cooper, CEO and Creative Director of World Patent Marketing. "It is projected to ...
    (Date:7/4/2015)... ... 2015 , ... Dating a real millionaire online can be more difficult. ... and strives to remove the worries from meeting partners. Recently, the site announced ... of 2015 and readers have responded with excitement. , “There's quite a few ...
    Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2
    ... and Diabetes Impact,the Profession, BETHESDA, Md., Feb. 7 ... lagging economy, entering the field of,podiatric medicine -- which ... in the right direction. A recent workforce study indicates,that ... to triple,their graduates between now and 2014 in order ...
    ... by the body can make the difference between your average ... the United States last year, reveals a new study in ... of Cell Press. , If this natural anti-cancer agent, ... might serve as a targeted chemotherapy for metastatic melanoma, a ...
    ... HQ, Offers Expanded Hours for Rapid HIV Testing,and ... Healing Our Land, Inc. and,Mass. Black Legislative Caucus ... Feb. 7 To commemorate the nation,s,eighth recognition ... of Massachusetts, Inc. (AAC) is collaborating to present ...
    ... animal fat and protein, risk did not increase, study claims ... in carbohydrates but high in animal fat and protein doesn,t ... women, a new study claims. , "One study is never ... in that it shows that a low-fat diet is no ...
    ... 7 AIDS Healthcare,Foundation (AHF) is proud to present ... art exhibition and auction to benefit its free,HIV/AIDS treatment, ... Vallarta, Cancun and Chiapas. Showcasing the work of notable ... of Latino art and culture will take place on ...
    ... Legendary Rock and Roll Hall of Famer, Marky Ramone of the ... ... NEW YORK, Feb. 7 The American Social Health Association,(ASHA) ... safer sex practices have never been more critical. Despite,hundreds of millions ...
    Cached Medicine News:Health News:Looking for a Career? A New Study Shows Demand for Doctors of Podiatric Medicine to Surge Over the Next Six Years 2Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3Health News:AIDS Action Committee Offers and Supports Variety of Events to Honor National Black HIV/AIDS Awareness Day 2Health News:Low-Carb Diets Better Than Low-Fat Diets at Preventing Diabetes 2Health News:Low-Carb Diets Better Than Low-Fat Diets at Preventing Diabetes 3Health News:Amigos y Amantes, Valentine's Day-Themed Art Auction to Benefit AIDS Healthcare Foundation's Mexico Clinics 2Health News:Amigos y Amantes, Valentine's Day-Themed Art Auction to Benefit AIDS Healthcare Foundation's Mexico Clinics 3Health News:Beating to the Drum of Safe Sex 2Health News:Beating to the Drum of Safe Sex 3
    Onyx Liquid Embolic System is a device utilized for the pre-surgical embolization of arteriovenous malformations (AVMs)....
    ... P2000 Pachymeter [i.e., PalmScan P2000] device ... biometer, which incorporates A-mode pulsed-echo ultrasound,technology, ... accurately measure the corneal thickness (CT) ... PalmScan P2000 includes two software user,interfaces; ...
    The Cordis ANGIOGUARD Capture Guidewire is the first embolic protection device shown in clinical testing to achieve a relative stroke reduction of 70% during carotid stenting procedures....
    ... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
    Medicine Products: